16/07/2026
What if Type 1 Diabetes could one day be treated by replacing the cells the disease destroys instead of relying on lifelong insulin?
For decades, people with Type 1 Diabetes have managed their condition with insulin injections because their immune system attacks the insulin-producing beta cells in the pancreas.
Now, researchers around the world are exploring therapies that could change that.
🔬 Scientists at Uppsala University used CRISPR gene editing to modify donor pancreatic islet cells so the immune system couldn't easily recognize them as foreign. In the first human recipient, the transplanted cells were still alive, producing insulin, and functioning four weeks after the procedure.
🧬 Meanwhile, Vertex Pharmaceuticals developed ximislecel, a stem cell-derived islet therapy that has helped participants with severe Type 1 Diabetes achieve insulin independence after one year in clinical trials. However, patients currently still require immunosuppressant medications to prevent rejection.
🩺 Researchers at Stanford Medicine are taking another approach by trying to reset the immune system itself. In animal studies, combining blood stem cell transplants with pancreatic islet transplants prevented or reversed Type 1 Diabetes. Human clinical trials are the next step.
While these treatments are not yet a cure and are not widely available, they represent a major shift in diabetes research. Instead of only managing blood sugar, scientists are working toward restoring the body's ability to produce insulin again.
With more than 500 million people worldwide living with diabetes, these advances offer hope that the future of treatment may look very different from the past.
This post is for educational purposes only and should not be considered medical advice. These therapies remain under research or have important limitations, and they are not currently suitable for everyone.
Follow Academically Global | OPRA, AMC, ADC, PSI, DHA, MOH, for more such healthcare insights.
Source: Uppsala University, Per-Ola Carlsson et al; Vertex Pharmaceuticals zimislecel trials; Stanford Medicine, 2025
